| 000 | 01416 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250516170020.0 | ||
| 264 | 0 | _c20131119 | |
| 008 | 201311s 0 0 eng d | ||
| 022 | _a1549-4713 | ||
| 024 | 7 |
_a10.1016/j.ophtha.2013.06.030 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWykoff, Charles C | |
| 245 | 0 | 0 |
_aTwo Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. _h[electronic resource] |
| 260 |
_bOphthalmology _cSep 2013 |
||
| 300 |
_a1945-6.e1 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRanibizumab |
| 650 | 0 | 4 | _aTomography, Optical Coherence |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVisual Acuity _xphysiology |
| 650 | 0 | 4 |
_aWet Macular Degeneration _xdiagnosis |
| 700 | 1 | _aBrown, David M | |
| 700 | 1 | _aCroft, Daniel E | |
| 700 | 1 | _aWong, Tien P | |
| 773 | 0 |
_tOphthalmology _gvol. 120 _gno. 9 _gp. 1945-6.e1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ophtha.2013.06.030 _zAvailable from publisher's website |
| 999 |
_c23056524 _d23056524 |
||